ProMIS Neurosciences (PMN) Stock Overview
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PMN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ProMIS Neurosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.14 |
| 52 Week High | US$39.75 |
| 52 Week Low | US$6.27 |
| Beta | -0.041 |
| 1 Month Change | -3.06% |
| 3 Month Change | -42.69% |
| 1 Year Change | -72.56% |
| 3 Year Change | -92.97% |
| 5 Year Change | -92.92% |
| Change since IPO | -98.81% |
Recent News & Updates
Shareholder Returns
| PMN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.9% | -2.0% | -1.1% |
| 1Y | -72.6% | 22.9% | 14.7% |
Return vs Industry: PMN underperformed the US Biotechs industry which returned 23% over the past year.
Return vs Market: PMN underperformed the US Market which returned 14.6% over the past year.
Price Volatility
| PMN volatility | |
|---|---|
| PMN Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PMN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PMN's weekly volatility has decreased from 26% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Neil Warma | www.promisneurosciences.com |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy.
ProMIS Neurosciences, Inc. Fundamentals Summary
| PMN fundamental statistics | |
|---|---|
| Market cap | US$14.69m |
| Earnings (TTM) | -US$29.28m |
| Revenue (TTM) | n/a |
Is PMN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$28.34m |
| Gross Profit | -US$28.34m |
| Other Expenses | US$947.21k |
| Earnings | -US$29.28m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PMN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 03:22 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ProMIS Neurosciences, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Francis Edward Hickman | Guggenheim Securities, LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Douglas Loe | Leede Financial Inc |